Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Colloids Surf B Biointerfaces ; 155: 61-70, 2017 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-28411476

RESUMEN

We report a facile route for the green synthesis of trimethyl chitosan nitrate-capped silver nanoparticles (TMCN-AgNPs) with positive surface charge. In this synthesis, silver nitrate, glucose, and trimethyl chitosan nitrate (TMCN) were used as silver precursor, reducing agent, and stabilizer, respectively. The reaction was carried out in a stirred basic aqueous medium at room temperature without the use of energy-consuming or expensive equipment. We investigated the effects of the concentrations of NaOH, glucose, and TMCN on the particle size, zeta potential, and formation yield. The AgNPs were characterized by UV-vis spectroscopy, photon correlation spectroscopy, laser Doppler anemometry, transmission electron microscopy, X-ray diffraction, and X-ray photoelectron spectroscopy. The catalytic activity of the TMCN-AgNPs was studied by the reduction of 4-nitrophenol using NaBH4 as a reducing agent. We evaluated the antibacterial effects of the TMCN-AgNPs on Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus using the broth microdilution method. The results showed that both gram-positive and gram-negative bacteria were killed by the TMCN-AgNPs at very low concentration (<6.13µg/mL). Moreover, the TMCN-AgNPs also showed high antibacterial activity against clinically isolated multidrug-resistant A. baumannii strains, and the minimum inhibitory concentration (MIC) was ≤12.25µg/mL.


Asunto(s)
Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Quitosano/química , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Nanopartículas del Metal/química , Plata/farmacología , Acinetobacter baumannii/crecimiento & desarrollo , Borohidruros/química , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Glucosa/química , Nanopartículas del Metal/ultraestructura , Pruebas de Sensibilidad Microbiana , Nitrofenoles/química , Oxidación-Reducción , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/crecimiento & desarrollo , Plata/química , Hidróxido de Sodio/química , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/crecimiento & desarrollo , Electricidad Estática
2.
Med J Aust ; 161(6): 356-60, 1994 Sep 19.
Artículo en Inglés | MEDLINE | ID: mdl-8090111

RESUMEN

OBJECTIVE: To develop an accurate presymptomatic test for Huntington's disease. METHOD: An improved polymerase chain reaction method was used to investigate the pattern of expansions of a CAG repeat sequence located in the 5' region of a gene recently found to produce the protein called Huntingtin. We documented the range of trinucleotide repeat expansions in the responsible gene in 82 affected individuals compared with 80 control subjects from a Western Australian population. RESULTS: The number of expanded repeats ranged from 40 to 73 in affected individuals and from 13 to 38 in normal controls. CONCLUSIONS: Polymerase chain reaction analysis of a CAG repeat sequence in the Huntington's disease gene clearly differentiated between normal and mutated alleles, providing an accurate diagnostic test for the disorder in individuals at risk. This predictive test has met with greater acceptance and demand than methods using family based linkage studies.


Asunto(s)
ADN , Pruebas Genéticas/métodos , Enfermedad de Huntington/diagnóstico , Mapeo Nucleótido/métodos , Reacción en Cadena de la Polimerasa/métodos , Secuencias Repetitivas de Ácidos Nucleicos/genética , Secuencia de Bases , Estudios de Casos y Controles , Análisis Mutacional de ADN/métodos , Femenino , Humanos , Enfermedad de Huntington/sangre , Enfermedad de Huntington/epidemiología , Enfermedad de Huntington/genética , Enfermedad de Huntington/prevención & control , Masculino , Datos de Secuencia Molecular , Aceptación de la Atención de Salud , Reproducibilidad de los Resultados , Factores de Riesgo , Sensibilidad y Especificidad , Australia Occidental/epidemiología
3.
Intern Med J ; 32(9-10): 445-50, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12380696

RESUMEN

BACKGROUND: Survivors of shipwrecks along the Western Australian coast may have introduced a mutation for variegate porphyria into the Aboriginal population prior to first settlement. AIMS: To assess the mutations responsible for variegate porphyria in Western Australian Aboriginal patients, particularly the R59W mutation, which is the most common cause of variegate porphyria in South Africa. METHODS: New cases of porphyria were diagnosed by biochemical separation of porphyrin subtypes. Single-stranded conformation polymorphism analysis and DNA sequencing of the protoporphyrinogen oxidase gene was performed on Aboriginal patients to define possible causative mutation sites. RESULTS: Of the 296 new cases of porphyria diagnosed in Western Australia from 1978 to 1998, six had biochemically proven variegate porphyria. Three of those cases occurred in Aboriginal patients. Evidence for a possible fourth Aboriginal case of variegate porphyria is described. The R59W founder mutation responsible for over 90% of variegate porphyria in South Africa was excluded. Two new mutations that predicted amino acid substitutions with significant effects on enzyme function were detected in conserved regions of the protoporphyrinogen oxidase gene in one Aboriginal variegate porphyria patient and the possible fourth case. CONCLUSION: Results suggest that the mutations causing variegate porphyria in the Western Australian Aboriginal population occur sporadically and were not inherited from shipwrecked sailors.


Asunto(s)
Nativos de Hawái y Otras Islas del Pacífico/genética , Porfirias Hepáticas/genética , Adulto , Análisis Mutacional de ADN , Femenino , Humanos , Persona de Mediana Edad , Polimorfismo Conformacional Retorcido-Simple , Porfirinas/sangre , Porfirinas/orina , Australia Occidental
4.
J Gastroenterol Hepatol ; 14(5): 427-30, 1999 May.
Artículo en Inglés | MEDLINE | ID: mdl-10355506

RESUMEN

BACKGROUND: Two mutations in a newly described gene, HFE, have been proposed as genetic markers for the inherited iron overload disease, genetic haemochromatosis. METHODS: We assessed the frequency of both mutations in a cohort of genetic haemochromatosis patients and compared these with a control population. The patients were genetic haemochromatosis patients from Western Australia whose diagnosis met strict criteria for phenotypic expression. Control patients had other liver disease where iron overload was excluded. RESULTS: Genomic DNA of 72 genetic haemochromatosis patients and 69 controls was examined for the C282Y and H63D mutations of the HFE gene using polymerase chain reaction amplification and restriction enzyme digestion. In genetic haemochromatosis patients, the C282Y mutation was homozygous in 64 of 72, giving a sensitivity of 89% (95% confidence interval 82-96%), heterozygous in five (7%) and absent in another three (4%), whereas none of the control subjects were homozygous. The H63D mutation was present in one genetic haemochromatosis patient and was not useful as a diagnostic marker. In this cohort of Western Australian patients with phenotypic expression of genetic haemochromatosis, the specificity of a homozygous C282Y mutation for genetic haemochromatosis was 100%. CONCLUSIONS: The results indicate that genotyping for the C282Y mutation is a useful test for the diagnosis of genetic haemochromatosis in clinical practice.


Asunto(s)
Pruebas Genéticas , Hemocromatosis/diagnóstico , Hemocromatosis/genética , Proteínas de la Membrana , Sustitución de Aminoácidos/genética , Estudios de Cohortes , Femenino , Frecuencia de los Genes , Genotipo , Antígenos HLA/genética , Proteína de la Hemocromatosis , Heterocigoto , Antígenos de Histocompatibilidad Clase I/genética , Homocigoto , Humanos , Masculino , Mutación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA